mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
-
Published:2023-10-18
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Riedmayr Lisa MariaORCID, Hinrichsmeyer Klara SonnieORCID, Thalhammer Stefan Bernhard, Mittas David Manuel, Karguth Nina, Otify Dina Yehia, Böhm Sybille, Weber Valentin Johannes, Bartoschek Michael DavidORCID, Splith Victoria, Brümmer Manuela, Ferreira Raphael, Boon NandaORCID, Wögenstein Gabriele Maria, Grimm ChristianORCID, Wijnholds JanORCID, Mehlfeld Verena, Michalakis Stylianos, Fenske StefanieORCID, Biel Martin, Becirovic ElvirORCID
Abstract
AbstractLarge genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, REVeRT enabled the reconstitution of full-length ABCA4 after intravitreal injection in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.
Funder
Deutsche Forschungsgemeinschaft Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference61 articles.
1. Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019). 2. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020). 3. Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol Ther. 18, 80–86 (2010). 4. van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N. & Schaffer, D. V. The delivery challenge: fulfilling the promise of therapeutic genome editing. Nat. Biotechnol. 38, 845–855 (2020). 5. Trapani, I., Tornabene, P. & Auricchio, A. Large gene delivery to the retina with AAV vectors: are we there yet? Gene Ther. 28, 220–222 (2021).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|